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Human lungs are constantly exposed to a large number of Aspergillus spores which are
present in ambient air. These spores are usually harmless to immunocompetent subjects
but can produce a symptomatic disease in patients with impaired antifungal defense. In a
small percentage of patients, the trachea and bronchi may be the main or even the sole
site of Aspergillus infection. The clinical entities that may develop in tracheobronchial location
include saprophytic, allergic and invasive diseases. Although this review is focused on invasive
Aspergillus tracheobronchial infections, some aspects of allergic and saprophytic tracheobronchial
diseases are also discussed in order to present the whole spectrum of tracheobronchial
aspergillosis. To be consistent with clinical practice, an approach basing on speciﬁc conditions
predisposing to invasive Aspergillus tracheobronchial infections is used to present the differences
in the clinical course and prognosis of these infections. Thus, invasive or potentially invasive
Aspergillus airway diseases are discussed separately in three groups of patients: (1) lung
transplant recipients, (2) highly immunocompromised patients with hematologic malignancies
and/or patients undergoing hematopoietic stem cell transplantation, and (3) the remaining, less
severely immunocompromised patients or even immunocompetent subjects.
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1. INTRODUCTION
Aspergillus forms a genus of ubiquitous, dimorphic molds present in soil, various types of organic debris,
water, indoor environment, and many other sites [1, 2]. Airborne Aspergillus spores are present virtually
everywhere in the atmosphere and are small enough (2-3µm) to be regularly inhaled into the lower airways
[1, 2]. However, due to efﬁcient natural antifungal defense mechanisms (i.e., mucosal barriers, macrophage
and neutrophil function) symptomatic pulmonary infections in otherwise healthy subjects are extremely
rare. Conversely, the impairment of these mechanisms (local or systemic) signiﬁcantly increases the risk of
airway colonization and progression to various Aspergillus-related pulmonary disorders [3–5].
Although more than 250 Aspergillus species have been identiﬁed, only a minority of them are
associated with human diseases [1, 6–8]. Aspergillus fumigatus is by far the most common pathogen
involved in 50–60% of all Aspergillus infections. Three other species which are a relatively common cause
of human diseases are: A. ﬂavus, A. niger,a n dA. terreus. Each of these species may be responsible for
10–15% of invasive human diseases [9–11]. Other species, for example, A. nidulans and A. ustus are only
occasionally identiﬁed and constitute less than 2% of isolates in patients with invasive Aspergillus infections
[9–11]. The predominance of A. fumigatus infections in patients with tracheobronchial involvement is even
more signiﬁcant. Karnak et al. reviewed 121 cases reported in the literature, and found that in 76 (63%)
patients with diverse Aspergillus tracheobronchial infections A. fumigatus was identiﬁed as the cause of
the disease. A. ﬂavus, A. niger,a n dA. nidulans were cultured in 5 (4.1%), 4 (3.3%), and 2 (1.7%) cases,
respectively, while, in 34 (28%), data regarding the species were not available [12].
1.1. Host-Fungus Relationships and Classiﬁcations of Aspergillus-Related
Respiratory Diseases
Thewideclinicalspectrumofpulmonaryaspergillosisreﬂectsthecomplexrelationshipbetweenthenumber
and virulence of organisms and the status of the patient’s antifungal defense. As different host-dependent
anatomical and immunological factors are the key prerequisite for the development of various clinical
entities, the general classiﬁcation of Aspergillus-related lung diseases is based on the type of the host-
fungus relationship. This includes saprophytic infections, allergic pulmonary diseases, invasive disease, and
toxic reactions [13]( Figure 1). Although this reasonable classiﬁcation presents a spectrum of Aspergillus-
related pulmonary diseases in humans, it does not address some aspects of these conditions. For example,
it does not reﬂect the anatomical location of the disease. Thus, the diagram shown in Figure 1 might be
further completed by adding subsequent rows in which anatomical location and/or disease subtype would
be presented.
Since the anatomical site of the disease plays a crucial role in development of speciﬁc signs and
symptoms as well as determines the diagnostic and therapeutic strategy, a simple, anatomical classiﬁcation
of Aspergillus-related respiratory disease is also used in clinical practice (Table 1).
In all anatomical locations, a spectrum of Aspergillus-related disorders involving various host-fungus
relationships (saprophytic, allergic, and invasive) may develop. It is important to realize that, on rare
occasions, one distinct Aspergillus-related entity may change to another; for example, an aspergilloma may
progress to semiacute invasive or invasive pulmonary aspergillosis (IPA) [13].
SomeoftheAspergillus-relatedrespiratorydiseasesarewelldeﬁnedandcommon;othersareunusual
but recognized; still, others are rare and controversial [6]. Aspergillus-related upper airway and pulmonary
diseases belong to the ﬁrst group. In a small percentage of patients, the trachea and bronchi may be the main
or even the sole site of Aspergillus infection. This condition is referred to as lower airway aspergillosis,
tracheobronchial aspergillosis, or Aspergillus tracheobronchitis.
2. TRACHOBRONCHIAL ASPERGILLOSIS
In 1991, Kramer and coworkers proposed a classiﬁcation of tracheobronchial aspergillosis. Similarly to
upper airway and pulmonary aspergillosis, the authors distinguished saprophytic, allergic, and invasive
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FIGURE 1: Classiﬁcation of the Aspergillus-related respiratory diseases based on their pathogenesis,
including the status of antifungal defense and the type of host-fungus relationship (upper and middle row,
respectively) (based on [13], modiﬁed).∗ In many patients, a true saprophytic nature of the infection is difﬁcult
to prove and might be questionable. Note, that in fact, not only vertical (showed with arrows), but also
horizontal relationships might exist in the middle and bottom rows (e.g., saprophytic forms can evolve into
invasive forms; relationships not shown); EEA: extrinsic allergic alveolitis, ABPA: allergic bronchopulmonary
aspergillosis, IPA: invasive pulmonary aspergillosis, ITBA: invasive tracheobronchial aspergillosis.
TABLE 1: Anatomical classiﬁcation of Aspergillus-related respiratory disease.
Aspergillus-related respiratory diseases
Aspergillus-related upper airway
diseases
Tracheobronchial Aspergillus diseases
Aspergillus-related diseases of lung
parenchyma
forms of Aspergillus tracheobronchial involvement. Based on clinical, bronchoscopic, and pathological
presentations, they were further subdivided into different clinical entities (Table 2)[ 14–16].
Recently, Patel et al. reported three patients with different forms of tracheobronchial aspergillosis
and presented their own, simpliﬁed, classiﬁcation of Aspergillus-related tracheobronchial diseases [17].
Although this classiﬁcation includes most of the known tracheobronchial manifestations of aspergillosis, it
also raises some doubts; for example, pulmonary aspergilloma was classiﬁed as tracheobronchial disease,
while endobronchial localization of Aspergillus fungal ball has not been mentioned [17, 18].
We realize that in view of the variety of different forms of Aspergillus tracheobronchial involvement
it is difﬁcult to propose a uniform and unequivocal classiﬁcation involving all entities. A review of
121 cases of Aspergillus-related endobronchial diseases reported in the literature, listing 13 different
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TABLE 2: Classiﬁcation of Aspergillus-related tracheobronchial diseases (based on [14–16]).
Host-fungus relationship
(type of tracheobronchial involvement)
Clinical characteristics of tracheobronchial
involvement
Saprophytic
Mucoid impaction
Obstructing bronchial aspergillosis
Allergic
Allergic bronchopulmonary aspergillosis (ABPA)
Bronchocentric granulomatosis
Invasive tracheobronchial aspergillosis (ITBA)
Aspergillus tracheobronchitis
Ulcerative Aspergillus tracheobronchitis
Pseudomembranous Aspergillus tracheobronchitis
bronchoscopic/pathologic descriptions and 17 different diagnoses, clearly demonstrates these difﬁculties
[12]. Nevertheless, we believe that the classiﬁcation presented by Kramer et al. is still valuable and
convincing. Therefore, it will be further used in this paper. However, since, from the original publication in
1991, a large body of papers has been published on different forms of tracheobronchial aspergillosis, new
data exceeding the original classiﬁcation will also be presented.
2.1. Allergic Forms of Tracheobronchial Aspergillosis
2.1.1. Asthma with Hypersensitivity to Aspergillus Antigen and Allergic
Bronchopulmonary Aspergillosis (ABPA)
Asthma with hypersensitivity to Aspergillus antigens as well as allergic bronchopulmonary aspergillosis
(ABPA) is well-deﬁned entities which can be considered as tracheobronchial manifestations of Aspergillus
infections. As both diseases have been extensively discussed in several articles published in the recent years
[1, 6, 19, 20], they will only be mentioned in this paper.
Clinical symptoms of asthma developing in patients with type I hypersensitivity to Aspergillus
antigens are not different from those found in patients allergic to other molds including Alternaria and
Penicillium [6]. Treatment is similar to that recommended for other patients with allergic asthma and
includes inhaled steroids and bronchodilators [1, 6].
ABPA usually develops in atopic individuals with extrinsic asthma or patients with cystic ﬁbrosis
and affects both, the bronchial compartment and adjacent lung tissue. Its pathogenesis involves Th2-
dependent, eosinophilic response to Aspergillus antigens [19]. Chronic inﬂammation of the airway walls
typically results in development of bronchiectasis and recurrent mucous plugging. Five stages of the
disease have been recognized with pulmonary ﬁbrosis being its ﬁnal consequence [1, 20]. Suppression
of the immunological response to Aspergillus antigens with systemic corticosteroids is a mainstay of ABPA
therapy. It aims at relieving acute symptoms and preventing progressive pulmonary ﬁbrosis [1, 19, 20].
Treatment with new azoles may have some beneﬁcial effect enabling the reduction of corticosteroid doses
[1, 19, 21]. Not all authors, however, conﬁrmed the efﬁcacy of antifungal agents [20].
2.1.2. Bronchocentric Granulomatosis
Bronchocentric granulomatosis is an effect of abnormal cell-mediated response to Aspergillus spp. This
inﬂammatory reaction involves the bronchi and bronchioles and is characterized by the formation of
necrotizing granulomas containing numerous inﬂammatory cells (mainly eosinophils) [1, 6, 13, 22]. This
is often associated with impaction of the airway lumen by a granular basophilic mucin and cellular debris
[22]. The Aspergillus hyphae were identiﬁed within the granulomas in 40–50% of cases, but typically there
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is no tissue or vascular invasion [13]. Two subtypes of bronchocentric granulomatosis are distinguished
by some authors [6, 14]. The ﬁrst is closely related to atopy and asthma. The second subtype may be
related to a variety of other diseases, such as rheumatoid arthritis, bronchogenic carcinoma, postradiation
pulmonary ﬁbrosis, and Wegener’s granulomatosis [17]. In some cases, bronchocentric granulomatosis may
overlap invasive forms of Aspergillus-related pulmonary diseases, namely, semiacute invasive pulmonary
aspergillosis (also termed chronic necrotizing aspergillosis) [1]. Corticosteroids are the mainstay of
treatment, but they are effective mainly in patients with atopy and asthma.
2.2. Saprophytic Forms of Tracheobronchial Aspergillosis
2.2.1. Mucoid Impaction
Mucoid impaction is deﬁned as intrabronchial retention of the inspissated mucoid secretions. Although it
has been found to be a nonspeciﬁc ﬁnding, inﬂammatory and allergic reactions to Aspergillus antigens are
probably the most common causes of this condition [23, 24]. Intrabronchial obstruction is often associated
with an inﬂammatory reaction in the airway wall. If the affected airway is large or dilated, the secretion may
be depicted on a chest radiograph or CT scan as tubular or branching opacities known as the ﬁnger-in-glove
sign [24].
Although mucoid impaction associated with hypersensitivity to Aspergillus antigens is usually
reported in patients with ABPA, it probably can also affect patients with asthma and hypersensitisation
to Aspergillus but without ABPA. [25, 26]. Other causes of mucoid impaction have been widely discussed
elsewhere [24]. Treatment of mucoid impaction associated with inﬂammatory response to Aspergillus is not
different from that used in patients with ABPA.
2.2.2. Obstructing Bronchial Aspergillosis
Obstructing bronchial aspergillosis was ﬁrst described by Denning et al. in three patients with AIDS
[27]. This was deﬁned as the presence of thick mucous plugs containing Aspergillus hyphae, with little
or no airway inﬂammation and no evidence of invasion or allergic reaction [15, 27] .T h ed i s e a s ei s
characterized by a subacute onset of symptoms, which include cough, hemoptysis, dyspnea, chest pain,
and expectoration of fungal casts [14, 27, 28]. Obstructing bronchial aspergillosis was also reported in
a heart transplant recipient whose chest radiograph performed on the third postoperative day revealed
middle lobe atelectasis. [29]. Multiple, endobronchial casts, containing Aspergillus hyphae were removed
during bronchoscopy. Although obstructing bronchial aspergillosis is regarded as a saprophytic form
of tracheobronchial aspergillosis, in immunocompromised patients, it can probably progress to invasive
tracheobronchitis [27–29].
It should be stressed that saprophytic, obstructing bronchial aspergillosis is an entity distinct from
invasive pseudomembranous Aspergillus tracheobronchitis which can also be associated with bronchial
obstruction by necrotic pseudomembranes (pseudomembranous, obstructive Aspergillus tracheobronchitis).
2.2.3. Other Saprophytic Forms of Aspergillus Tracheobronchial Involvement
Another saprophytic Aspergillus tracheobronchial infection which had not been included in classiﬁcation
presented by Kramer et al. is saprophytic Aspergillus infection involving bronchial anastomoses. This
entity has been described in lung transplant recipients. Devascularization of the bronchial anastomosis
in the early posttransplantation period may result in sloughing of epithelial tissue into the airway lumen
[30]. This necrotic debris may serve as nourishment for fungal hyphae germinating from airborne spores.
The intensive immunosuppression in the early posttransplantation period is an important factor promoting
fungal growth. Nunley et al. deﬁned saprophytic fungal infection as positive culture of bronchial washing
and presence of fungal organisms in biopsy samples from bronchial anastomosis [30]. In their series, the
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incidence of saprophytic fungal infection of bronchial anastomosis was as high as 24.6%, with Aspergillus
spp. being responsible for two thirds of the cases. The median time from transplantation to diagnosis
of saprophytic fungal infection was 35 (range 13–159) days [30]. All patients with anastomotic fungal
infection were intensively treated with intravenous and nebulized amphotericin B and oral itraconazole.
This intensive treatment and, particularly, the complications which developed in some patients including
bronchomalacia, bronchial stenosis and hemorrhage raise some doubt about the truly saprophytic nature
of these infections. We suppose, that in some patients fungal infection of bronchial anastomosis which is
initially limited to necrotic tissue and deﬁned as saprophytic may easily progress to locally invasive fungal
infection. If so, the borderline between saprophytic fungal infection of bronchial anastomosis and local,
invasive Aspergillus tracheobronchitis in lung or heart and lung transplant recipients might be quite elusive
(see further: Aspergillus tracheobronchitis in patients after lung transplantation).
Aspergillus growth on silk sutures closing a bronchial stump is another example of saprophytic
fungal-host relationship. This infection usually develops 6–12 months after lung resection and can spread to
mucous plug or debris as well as granulation tissue located in the stump. The removal of the thread solves
the problem, and usually no antifungal therapy is necessary [31]. A much longer latency period between
lung resection and development of bronchial stump aspergillosis, ranging between 4 and 7 years, was also
reported [32, 33]. Noppen et al. found that, albeit bronchoscopic removal of the silk thread seems to be
the ﬁrst choice therapy, treatment with oral itraconazole can also result in resolution of infection [32]. Le
Rochais et al. demonstrated that bronchial stump aspergillosis is not speciﬁc for silk thread but can also
affect patients in whom nylon threads were used [34].
Since invasion of bronchial mucosa was reported in patients with bronchial stump aspergillosis [32],
this is yet another example that the line between saprophytic and invasive Aspergillus infection may not be
well deﬁned, and borderline cases can be expected in clinical practice.
Aspergillus can overgrow necrotic debris and mucous plug on the surface of endobronchial tumors.
We observed a thick layer of Aspergillus hyphae covering an endobronchial carcinoid tumor (data not
published). Initially, this caused a diagnostic challenge. A similar situation was reported by others [35].
2.3. Invasive Tracheobronchial Aspergillosis (ITBA)
While invasive pulmonary aspergillosis centered on the airways accountsfor 14–34% of invasive pulmonary
aspergillosis (IPA), invasive tracheobronchial aspergillosis (ITBA) is a relatively rare manifestation of
Aspergillus-related lung disease [36]. ITBA has been described as an isolated or dominating local
manifestation only in a small number of patients (6.9% of patients with intrathoracic aspergillosis in three
case series analyzed by Kemper et al.) [37]. In the majority of cases, ITBA is probably associated with
IPA, which is the most common form of Aspergillus invasion. [38, 39]. Both, IPA and ITBA, predominantly
affect severely immunocompromised patients [39]. ITBA has also been reported in patients with various
chronic diseases without severe immune suppression (e.g., diabetes) and even in immunocompetent subjects
[40–42].
Since the most reliable criterion of invasive fungal airway disease is demonstration of tissue invasion
and damage caused by hyphae [15, 43, 44], bronchoscopy with biopsy, microscopy, and culture is the only
way to conﬁrm invasive Aspergillus tracheobronchial infection in the clinical setting [16].
Basing on the bronchoscopic or pathologic appearance, three different invasive forms of tracheo-
bronchial aspergillosis were described: Aspergillus tracheobronchitis, ulcerative Aspergillus tracheobron-
chitis, and pseudomembranous Aspergillus tracheobronchitis [14]. Denning and coworkers proposed to
apply the term “Aspergillus tracheobronchitis” to tracheobronchial disease caused by Aspergillus spp.
which is characterized by the evidence of bronchial and/or tracheal inﬂammation and excessive mucus
production without invasion of the bronchial mucosa on biopsy [15]. The features of the ulcerative forms
include the presence of variable, ulcerative, or plaque-like lesions in the bronchial walls. This form has
been most commonly recognized in patients with AIDS and heart-lung or lung transplant recipients [15].
Pseudomembranous form of ITBA is characterized by extensive involvement of the lower airways, with
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sloughing of necrotic epithelium which, together with endobronchial mucus, form the pseudomembranes
overlying the mucosal surface. This form has usually been found in severely immunocompromised hosts
with hematologic malignancies [14, 15, 37, 45]. It is important, however, to be aware that the morphological
appearance of airway aspergillosis may easily change and that different forms of Aspergillus-related
invasive airway involvement may coexist. Kramer et al. hypothesized that these three forms represent a
progressive evolution of the disease ranging from mild bronchitis to widespread pseudomembranous diffuse
disease [14]. Many publications seem to conﬁrm this point of view. Thus, it should be stressed that although
this classiﬁcation will be further used to present different aspects of ITBA, it has rather an educational than
true clinical value.
A novel classiﬁcation of isolated ITBA has recently been proposed by Wu et al. According to
bronchoscopicﬁndings,theauthorsrecognizedfourtypesofinvasiveairwayaspergillosis:typeI:superﬁcial
inﬁltration, type II: full-layer involvement, type III: occlusive, and type IV: mixed [46]. Although at ﬁrst
glance this classiﬁcation signiﬁcantly differs from that presented by Kramer et al., both classiﬁcations have
much in common. They both classify several disease stages from relatively mild to severe and more complex
forms. As reliability of visual bronchoscopic assessment of the depth of bronchial wall involvement may be
questionable, descriptive terms used by Kramer et al. seem more justiﬁed [14, 46].
Keeping in mind three different forms of invasive or potentially invasive Aspergillus airway
disease, an approach basing on speciﬁc conditions predisposing to tracheobronchial infections rather
than on the macroscopic and/or pathologic appearance might be of more use for a clinician. This is
justiﬁed not only by the fact that speciﬁc groups of high-risk patients are usually treated by different
specialists, but also by the fact that the same form of Aspergillus airway involvement may have a
different clinical course and prognosis, highly dependent on a variety of host factors. Therefore, invasive or
potentially invasive Aspergillus airway diseases will be further presented in three main groups of patients:
(1) lung transplant recipients, (2) highly immunocompromised patients with hematologic malignancies
and/or patients undergoing hematopoietic stem cell transplantation, and (3) the remaining, less severely
immunocompromised patients, or even immunocompetent subjects.
2.3.1. Aspergillus Tracheobronchitis in Patients after Lung Transplantation
Lung transplant recipients are a unique subset of patients which are particularly susceptible to Aspergillus
bronchial invasion. This is a consequenceof continuous exposure of the transplanted organ to environmental
pathogens and, simultaneously, the use of aggressive immunosuppressive therapy [47, 48]. In a group of 121
patients with endobronchial aspergillosis identiﬁed by the literature review, 80 (66%) were lung transplant
recipients [12].
In 2000, Nathan et al. reported a relatively high incidence of Aspergillus-related endobronchial
abnormalities in lung transplant recipients. These authors found endobronchial involvement in 7 out of
38 patients (18.4%), and, at least in 4 of these patients, bronchial wall invasion was demonstrated [49]. One
year later, Mehrad et al. presented the retrospective analysis of the large series of 133 patients and reviewed
the literature on Aspergillus infections in lung transplant recipients. The incidence of isolated Aspergillus
tracheobronchitis was 5% in the authors’ series and 4% in pooled published data [47]. The incidence of
Aspergillus tracheobronchitis was only slightly lower than the incidence of IPA (5% versus 8% and 4%
versus 5% in Mehrad et al. and pooled published data, resp.). Virtually the same results were presented in a
Spanish study (6% and 8% of Aspergillus tracheobronchitis and IPA, resp.) [48]. Interestingly, the review of
40 papers, which reported 159 lung transplant recipients who developed Aspergillus infections, showed that
tracheobronchitis was the most common form of Aspergillus infection responsible for 37% of cases. IPA,
Aspergillus infections of bronchial anastomosis and disseminated aspergillosis, accounted for 32%, 20%,
and 10% of cases, respectively [50].
Itseemsthat,incertainpatients,theriskofpostoperativeITBAdevelopmentdependsonpreoperative
airway colonization by Aspergillus. This was shown by Helmi et al. in patients with cystic ﬁbrosis
(CF). ITBA developed only in patients with persistent preoperative airway colonization with A. fumigatus
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while none of the patients who had not been colonized prior to surgery developed any form of invasive
aspergillosis [51]. The authors noted that antifungal prophylaxis did not prevent the development of ITBA,
and amphotericin B therapy (with or without endobronchial debridement of necrotic tissue) was required to
clear the infection in all patients [51]. A recent study revealed that despite voriconazole prophylaxis, the risk
of posttransplant fungal infection in recipients with features of the mold infection in the explanted lung was
signiﬁcantly higher than in patients without mold infection, 43 and 14%, respectively [52]. Results of other
studies do not, however, conﬁrm the relationship between pre-transplant Aspergillus airway colonization
and the risk of posttransplant colonization and/or Aspergillus infection [53, 54].
The incidence of isolated Aspergillus tracheobronchitis is highest in the ﬁrst year after transplan-
tation, with virtually all cases diagnosed within the ﬁrst three-to-six months after transplantation [47, 48,
51]. According to the review by Singh and Husain, the median time from transplantation to diagnosis of
Aspergillus tracheobronchitis and/or bronchial anastomotic infection was 2.7 months [50].
All patients with Aspergillus tracheobronchitis seen by Mehrad et al. were asymptomatic, while in
otherseries,theclinicalpresentation,aswellasendoscopicappearanceoftheisolatedtracheobronchitiswas
variable. One of the reviews showed that none of 13 patients who developed Aspergillus tracheobronchitis
and/or bronchial anastomotic infection had fever [50]. Monitoring of the serum Aspergillus galactomannan
(GM) level plays no role in the diagnosis of IPA and ITBA in lung transplant recipients. One study showed
positive results of the test in only 28.5% of patients with IPA and in none of four patients with ITBA
(sensitivity 0%) [55]. Another paper from the same group of authors demonstrated that albeit overall
diagnostic sensitivity of GM measurement in BALF was higher (60%), the level of GM in the sole patient
with ITBA was below the cut-off value [56], hence, the important role of surveillance bronchoscopy in early
diagnosis of isolated Aspergillus tracheobronchitis [47].
The vast majority of Aspergillus-related tracheobronchial lesions in patients who underwent
lung transplantation occurred in the transplanted lung and involved the anastomosis line [47–50].
Aspergillus fumigatus was responsible for almost 90% of all tracheobronchial infections [50]. The
bronchoscopic appearance of the airway lesions included pseudomembrane formation, bronchial stenosis
in the anastomosis line, ulcerations, and black eschar [47–49]. Severe complications may develop including
a nontraumatic disruption of the anterolateral, ﬁbrocartilaginous tracheal wall, as reported by Aerni et al.
[57]. The probable pathophysiologic basis for this complication was fungal invasion of the blood vessels
resulting in a critical compromise of local blood supply [57].
Prognosis for lung transplant patients with Aspergillus tracheobronchitis is favorable as compared
to IPA and disseminated infections. Mortality rate calculated from 40 studies was 23.7% in patients
with Aspergillus tracheobronchitis and/or anastomotic infection versus 81.8% and 50% in patients with
IPA and disseminated infections, respectively [50]. In the series presented by Sole et al., Aspergillus
tracheobronchitis resulted in a 14% mortality rate as compared to 78% in IPA [48]. All six patients treated
by Mehrad et al. survived, and pooled data from all series analyzed by these authors showed the mortality
rate 18% [47].
The most common therapeutic option for lung transplant recipients with Aspergillus tracheobron-
chitis was oral itraconazole or intravenous amphotericin B. Some centers used aerosolized amphotericin
B as adjunctive treatment. A substantial number of patients required additional local treatment including
bronchoscopic debridement, balloon dilatation, laser treatment, and/or stent placement [47–49]. It should
be noted, that none of the patients progressed to invasive pneumonia [47].
Prophylactic administration of the antifungal agents has been shown to decrease the incidence of
invasive fungal infection after lung transplantation. However, there is no uniformly accepted strategy, and
different drugs are used in lung transplant centers throughout the world [58, 59]. They include nebulized
amphotericin B, oral voriconazole, or itraconazole, alone or in combinations [59, 60]. Since the use of
aerosolizedmedicationsmaysigniﬁcantlyreducetheirtoxicsystemiceffectsandpotentialdruginteractions,
theyareanattractiveoption[61].Thisespeciallyregardsliposomalandlipidcomplexformsofamphotericin
B which can be administered three times a week or even once a week, respectively [62, 63].
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(a) (b)
FIGURE 2: Al a r g eAspergillus ulcer in the posterior wall of the left main stem bronchus (a). Similar
ulceration in the posterior wall of the right main stem bronchus covered by ﬁbrin and tissue debris (b).
2.3.2. Aspergillus Tracheobronchitis in Immunocompromised Patients with Hematological Malignancies
Although Aspergillus airway infection may complicate the course of different malignant diseases, the
highest risk affects severely immunocompromised patients with hematological malignancies. In one of the
early reports, 6 out of 9 patients with fungal tracheobronchitis had underlying malignant diseases and in 3 of
them different leukemias were diagnosed [64]. In the later review reporting 20 cases of pseudomembranous
ITBA, an underlying malignant disease of the hematopoietic system was found in 13 (65%) patients
[45]. The proportion of lung versus airway involvement in patients with hematological malignancies
is signiﬁcantly different than that in previously discussed patients undergoing lung transplantation; IPA
is responsible for 80–90% of Aspergillus infections, while tracheobronchial aspergillosis is much less
common. It is estimated that approximately 10% of patients with invasive aspergillosis may present relevant
signs of tracheobronchial invasion, either alone or with pulmonary parenchyma involvement [6].
All the three forms of ITBA listed in the classiﬁcation by Kramer et al. (Table 2) can probably
develop in patients with hematological malignancies. However, a signiﬁcant predominance of the ulcerative
and pseudomembranous forms was found in reports published up to date. If the supposition that the three
forms of Aspergillus tracheobronchitis represent a progressive spectrum of fungal invasion is true, the
predominance of more invasive forms in patients with severe immunosuppression can be easily understood.
This is also consistent with observations that the course of Aspergillus airway infection in these patients is
severe, and the prognosis is signiﬁcantly worse than in patients after lung transplantation.
Some less common forms of invasive airway aspergillosis have also been reported in patients
with hematological malignancies. In a severely immunocompromised patient with the graft versus host
disease (GvHD) which developed after allogeneic bone marrow transplantation due to low-grade non-
Hodgkin lymphoma, Irani et al. found multiple white papular lesions of the tracheal mucosa and plaque-like
vascularized changes. Pathological examination of the biopsy specimen conﬁrmed invasion with numerous
fungal hyphae consistent with ITBA [39]. Multiple, small, 3 to 5mm in diameter nodules in both main
stem and lobar bronchi were the dominating picture in a patient with ITBA and acute lymphoblastic
leukemia (ALL) treated by Sancho et al. [65]. It should also be realized that in many patients with ITBA
the endobronchial appearance might not be uniform and include different lesions, even in the context of
t h es a m ef o r mo fAspergillus tracheobronchitis. For example, ulcerative lesions may be less obvious when
covered by ﬁbrin, as compared to uncovered ulcers (Figure 2(a) and 2(b)).
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Moreover, features of different forms of Aspergillus tracheobronchitis can be found in the same
patient. We observed large ulcerative lesions, being the most relevant feature of fungal invasion in both main
stem bronchi, coexisting with extensive pseudomembranous bronchitis seen in the peripheral bronchi [66].
The coexistence of different forms of Aspergillus tracheobronchitis has also been demonstrated by other
authors.Arrieroetal.foundsimultaneousobstructiveandpseudomembranousnecrotizingtracheobronchitis
due to Aspergillus ﬂavus in a diabetic patient with ALL [67]. Buchheidt et al. reported a patient with
Hodgkin lymphoma and pseudomembranous form of tracheobronchial aspergillosis in whom patchy
ulcerations were also found in the trachea and bronchi [68]. Van Assen et al. described “yellowish plaques,
ulcerations and pseudomembranes” seen during bronchoscopy in a patient who underwent hematopoietic
stem cell transplantation (HSCT) due to acute myeloid leukemia (AML) and who subsequently developed
Aspergillus tracheobronchitis [69]. It is of note that many of the invasive Aspergillus tracheobronchial
infections affected patients treated with HSCT who subsequently developed GvHD requiring further,
intensive immunosuppressive therapy [39, 69–71].
Unlike Aspergillus tracheobronchitis in lung transplant recipients, ITBA in patients with hematolog-
ical malignancies is usually symptomatic. Dyspnea, inspiratory wheezes, fever, and nonproductive cough
belong to the most commonly reported symptoms [66, 68–70]. Airway obstruction may result in atelectasis
and severe respiratory failure [72]. It should be emphasized that, in patients with isolated tracheobronchitis,
the chest radiograph and CT scan may not reveal pulmonary lesions [36, 67, 69, 70]. Different features
and extent of pulmonary involvement, from small parenchymal or peribronchial inﬁltrations to larger
areas of consolidation and nodules, can be seen in patients with simultaneous lung involvement [38, 39,
65, 66]. In some patients, CT scanning, positron emission tomography-CT scanning, and endobronchial
ultrasonography (EBUS) can demonstrate bronchial wall involvement with bronchial lumen narrowing
[38, 71]. Bronchoscopy plays a crucial role in endobronchial disease assessment and specimen collection
for microbiological and pathological evaluations. However, due to Aspergillus capability to invade blood
vessels, bronchial biopsies may carry the additional risk of bleeding, particularly that many patients have
a low platelet count [73]. Fatal hemorrhage was reported when attempts have been undertaken to remove
obstructing pseudomembranes [74]. Recently, Casal et al. have shown that EBUS-guided transbronchial
needle aspiration biopsy (EBUS-TBNA) can help to obtain adequate tissue specimens in patients in whom
the results of endobronchial specimen evaluation were inconclusive [71].
The value of other methods in diagnosing ITBA, including the serum level of circulating GM, is
uncertain. The serum concentration of GM was elevated in the patient described by Machida et al. [70]
but remained low in a series of 6 serum samples in a patient treated by Van Assen et al. [69]. In the
small series of patients with pseudomembranous Aspergillus tracheobronchitis reported by Tasci et al., one
patient had elevated level of serum Aspergillus antigen, while borderline and negative results were found
in two other patients, respectively [45]. Low serum Aspergillus antigen level in a heart transplant recipient
with pseudomembranous Aspergillus tracheobronchitis has been recently reported by Ramos et al. [75]. To
explain these differences, Van Assen et al. presented two hypotheses. The ﬁrst assumes that in some patients
the fungal invasion is limited to the superﬁcial layer of the airway mucosa and, thus, is not sufﬁcient to cause
the spread of Aspergillus antigens into the circulating blood. The alternative explanation points out a false
negative ELISA reactivity as a cause of low serum GM level [69].
There are some data that BALF, or maybe even bronchial washing, might be a more accurate
diagnostic material in patients with ITBA as compared to peripheral blood. In one of our patients, we found
a negative result of serum Aspergillus GM measurement while the bronchoalveolar lavage ﬂuid (BALF)
examination gave a positive result. Also De Rosa et al. showed that BALF GM concentrations in a diabetic
patient with pseudomembranous Aspergillus tracheobronchitis signiﬁcantly exceeded GM concentrations
in serum [76].
In earlier reports, amphotericin B was invariably used to treat patients with invasive Aspergillus
tracheobronchitis (Table 3). In the recent years, combined treatment including amphotericin B plus
caspofungin or amphotericin B plus voriconazole as well as monotherapy with voriconazole has been the
predominant therapeutic options. This is consistent with the latest Infectious Diseases Society of America
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guidelines which recommend voriconazole for primary treatment of invasive Aspergillus tracheobronchitis
[77]. Alternative treatments include liposomal or lipid complex form of amphotericin B, caspofungin,
micafungin, posaconazole, and itraconazole [77]. Due to poor penetration of antifungal agents into the
fungal masses, bronchoscopic removal of pseudomembranes and mycelial masses seems a reasonable
component of treatment, but this might be associated with signiﬁcant risk of severe bleeding [74].
The prognosis in severely immunocompromised patients with hematological malignances and ITBA
is signiﬁcantly worse than in lung transplant recipients. None of the three patients with hematological
malignancies reported by Tasci et al. survived [45]. Searching through the papers published in the last
15 years, we found 17 reports presenting the outcome in 19 patients with ITBA and hematological
malignancies. The data from these papers are summarized in Table 3. The mortality rate related to
Aspergillus infection was as high as 72.2% (only four patients survived). Buchheidt et al., who successfully
treated one patient with Hodgkin disease and pseudomembranous Aspergillus tracheobronchitis, stress that
the key factors which warrant a favorable outcome are an early diagnosis involving bronchoscopy with
culture and pathology as well as an adequate antifungal therapy [68]. Although 12 out of 19 patients with
isolated Aspergillus tracheobronchitis complicating various malignant and nonmalignant diseases reported
byWuetal.survived,theonlypatientwithunderlyinghematologicalmalignancy(non-Hodgkinlymphoma)
died of cerebral dissemination of aspergillosis [46].
Thus, we believe that the prognosis in patients with ITBA depends more on the underlying condition
than on the form of Aspergillus airway involvement which, to a large extent, is a consequence of the
immune status of the infected host. This seems to be conﬁrmed by the comparison of prognosis in
lung transplant recipients and patients with hematological malignancies (see above). Assuming that the
diagnosis of diverse forms of ITBA is based on the macroscopic appearance of endobronchial lesions, we
cannot share the opinion of Tasci et al., that the term “ulcerative Aspergillus tracheobronchitis” should
be reserved for patients with limited involvement of the tracheobronchial tree and that this entity is
invariably associated with favorable prognosis [45]. In patients, reported by Van Assen et al. and by
Krenke et al., ulcerative lesions were the important features of airway involvement and both patients
died because of invasive fungal infection [66, 69]. Hence, there are probably at least two different
subforms of ulcerative tracheobronchitis signiﬁcantly differing in prognosis: one seen around the suture
line in lung transplant recipients (reported to have a relatively favorable outcome) and the second
which affects severely immunocompromised patients (e.g., HSCT recipients, patients with hematologic
malignancies treated with highly cytotoxic regimens) and frequently coexists with the pseudomembranous
form of tracheobronchitis. The prognosis in the second group of patients is poor and similar to that in
pseudomembranous Aspergillus tracheobronchitis. Severe bleeding and respiratory failure are common
complications responsible for a high mortality rate in these forms of airway invasive aspergillosis
[38, 65, 69].
2.3.3. Aspergillus Tracheobronchitis in AIDS Patients
An overall incidence of Aspergillus infections in HIV-infected subjects ranges between 0 and 12%
[16, 28, 78]. Invasive aspergillosis usually affects patients with advanced AIDS. Neutropenia, an impaired
neutrophil and monocyte-derived macrophage function, and/or corticosteroid therapy are important factors
contributing to disease development [16, 79, 80].
The majority of the reports on tracheobronchial aspergillosis in this patients group come from the
80s and the 90s of the XX century [27, 37, 79, 81]. In the review of 342 patients with AIDS and pulmonary
aspergillosis, Myelonakis et al. identiﬁed 23 (7%) cases in which infection mainly involved large airways
[82]. ITBA was diagnosed in 3 out of 93 AIDS patients (3.2%) with deﬁnite IPA [82]. Besides obstructing
Aspergillus tracheobronchitis representing saprophytic Aspergillus airways involvement, different invasive
forms of tracheobronchial aspergillosis have been reported. They include ulcerative or plaque-like and
pseudomembranous (necrotizing) Aspergillus tracheobronchitis [37, 79]. Some of the reported cases are
difﬁcult to classify due to incomplete bronchoscopic and pathologic data [81].
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Patients with AIDS and ITBA are usually symptomatic, with cough, dyspnea, and fever being the
most commonly reported symptoms [37, 79, 81]. Physical examination may reveal wheezes. In a series
of four patients reported by Kemper et al., chest radiograph was abnormal in two patients showing patchy
multinodular or interstitial inﬁltrates [37]. Similarly, bilateral alveolar inﬁltrates were revealed in patient
treated by Conte et al., while, in a patient reported by Pervez et al., the chest radiograph was normal [79, 81].
Contrary to variable and nonspeciﬁc results of radiographic examination, bronchoscopy with pathology
and culture of bronchial specimens plays a key role in diagnosis [37, 83]. The endobronchial appearance
of invasive aspergillosis may include erythematous or edematous mucosa, ulcers, white or grayish lesions
formingplaques,orpseudomembranesorliningscoveringbronchialmucosa,causingevenairwayocclusion
[37, 79, 81, 83].
Due to limiter number of reports, the assessment of the prognosis and optimal therapeutic strategy
is not easy. Three of the four patients seen by Kemper et al. were treated with intravenous amphotericin B
followed by oral itraconazole, and one patient received itraconazole followed by intravenous amphotericin
B. One patient was lost to follow up and one patient died of disseminated aspergillosis shortly after the
diagnosis. In two other patients, initial clinical response was noted but both patients died between 6 and
12 months after disease onset. The true role of the Aspergillus infection in the fatal outcome of these two
patient is equivocal [37]. An initial response has also been noted in a patient treated with oral itraconazole,
ﬂucytosine, and nebulized amphotericin B [81].
2.3.4. Aspergillus Tracheobronchitis in Other Groups of Patients
Invasive tracheobronchial aspergillosis has also been reported in other groups of patients. Several cases
of Aspergillus tracheobronchitis in immunocompetent and previously healthy subjects were reported [42,
46, 84–86]. However, in the majority of other publications, different underlying conditions in patients who
developed ITBA were diagnosed. They include various malignant diseases, and for example, thymoma,
breast, lung, esophageal and renal carcinomas and chronic diseases, for example, diabetes mellitus, chronic
obstructive pulmonary disease, solid organ transplantation other than lung, and posttuberculous tracheal
stenosis [40, 41, 46, 75, 76, 87–89].
In this heterogeneous group of patients, the spectrum of ITBA-related symptoms can be very wide
and range from chronic dry cough and decreased appetite to high fever, severe respiratory distress, and rapid
development of respiratory and multiorgan failure [85, 86, 90].
Bronchoscopic appearance did not signiﬁcantly differ from that found in other patients groups
although the extent of endobronchial changes might be limited [84, 88]. Pseudomembranous form of ITBA
was reported in the majority of patients. [40, 41, 75, 84, 85, 87, 88]. Serum GM concentration was measured
in a patient who had undergone heart transplantation complicated by pseudomembranous Aspergillus
tracheobronchitis, but the level was low and, hence, not diagnostically useful [75]. On the other hand,
strongly positive results of Aspergillus antigen testing in serum were observed in an immunocompetent
patient in whom both tracheobronchial and pulmonary invasive Aspergillus diseases were diagnosed [90].
Intravenous itraconazole with or without nebulized amphotericin B and bronchoscopic debridement
was most commonly applied initial therapy in patients treated by Wu et al. [46]. Alternatively, some patients
received liposomal amphotericin B, nebulized amphotericin B, or voriconazole [46]. The mean treatment
duration was 25 (range 8 to 47) days. In the several case reports, different treatment modalities were
relatively equally distributed and included amphotericin B, voriconazole or itraconazole [40, 75, 85–88].
The prognosis seems to be largely dependent on the underlying disease. In the series presented by
Wu et al., all ﬁve patients who had no or had nonmalignant underlying diseases survived. Conversely,
6/13 (46%) of patients with a malignant underlying disease died [46]. In four of them, the cause of
death was directly related to Aspergillus infection. A relatively good prognosis in patients with ITBA and
nonmalignant underlying disease was also found in other publications. Only one of the ﬁve reported patients
died (mortality rate 20%) [40, 41, 75, 87]. Considering patients with Aspergillus tracheobronchitis and no
underlying diseases, two of the three patients survived, but one, a 44-year-old man treated by Oh et al., died
due to refractory septic shock and hypoxemia [84–86].
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3. SUMMARY
Although tracheobronchial Aspergillus infections are relatively rare, they include a wide spectrum of
different entities. Host-fungus relationship plays a key role in the development of these diseases. Thus,
conditions affecting host organism and predisposing to tracheobronchial infections are critical in predicting
the form, clinical course of the disease, and prognosis. The most serious, invasive tracheobronchial diseases
affect patients with profound impairment of the antifungal defense, namely, patients with hematologic
malignancies and/or patients undergoing hematopoietic stem cell transplantation. The prognosis in these
subjects is generally poor, with mortality rate up to 70%. Key factors which may warrant a favorable
outcome are an early diagnosis in adequate antifungal therapy. Bronchoscopy plays the most important role
in endobronchial disease assessment and enables specimen collection for microbiological and pathological
evaluation.
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